BiotechTube
Viome Life Sciences

Viome Life Sciences

Bellevue, United States· Est.
viomelifesciences.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Viome Life Sciences is a private biotech firm pioneering a novel approach to chronic disease and cancer by analyzing the functional activity of the human microbiome. Its core technology platform leverages metatranscriptomics and AI to decode biological data from over 300,000 specimens, aiming to shift healthcare from treatment to prevention. The company has secured significant funding, including a $54 million raise, and is expanding a collaboration with GSK to develop new therapeutic interventions for cancers and autoimmune diseases.

OncologyAutoimmune DiseasesChronic Diseases

Technology Platform

Metatranscriptomics and machine learning/AI platform analyzing functional microbial and human gene expression to decode biology for disease prediction, prevention, and treatment.

Opportunities

The global chronic disease epidemic and shift towards preventive healthcare create a massive market for predictive diagnostics.
The collaboration with GSK provides a validated pathway into pharmaceutical development and de-risks therapeutic programs.
The company's large proprietary dataset (>300,000 specimens) is a competitive asset for AI model training.

Risk Factors

High scientific risk in establishing causative links between microbiome activity and complex diseases.
Navigating regulatory pathways for novel diagnostics and microbiome-based therapeutics is long and uncertain.
Intense competition in the microbiome and AI-driven drug discovery spaces from both startups and large pharma.

Competitive Landscape

Viome competes in the broad microbiome and precision health space, facing competition from diagnostic companies (e.g., DayTwo, ZOE), microbiome therapeutics firms (e.g., Seres Therapeutics, Vedanta Biosciences), and large tech and pharma companies investing in AI for biology. Its differentiation lies in its specific focus on metatranscriptomics (functional activity) and its integrated three-pillar business model.

More companies in Microbiome Therapeutics →More companies in United States →